

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|---|

No equality issues were raised during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|--|

No equality issues have been raised in the submissions, expert statements or academic reports.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|--|

No equality issues were identified by the Committee.
--

- | |
|---|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group? |
|---|

Not applicable, as ipilimumab is provisionally not recommended for the treatment of advanced metastatic melanoma in the ACD.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

6. Have the Committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, in the summary table in the ACD.

Approved by Associate Director (name): Janet Robertson.....

Date: 10/12/12

Final appraisal determination

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

No equality issues have been identified during the consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendation has not changed after the consultation period.

3. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

The recommendation has not changed after the consultation period.

4. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, the summary table of the final appraisal determination states that no equality issues have been identified during the scoping exercise or the course of the appraisal.

Approved by Centre or Programme Director (name): Meindert Boysen.....

Date: 10/12/2012